https://www.scirp.org/journal/jbise
J. Biomedical Science and Engineering,
2025, Vol. 18, (No. 2), pp: 33-43

A Multidisciplinary Approach: Advancements in Regenerative Medicine and Biotechnology for CNS Repair

Hannah K. Markopoulos

Department of Natural Sciences, Life University, Marietta, Georgia, USA

Correspondence to: Hannah K. Markopoulos, hannah.markopoulos@gmail.com
Keywords: Neurodegenerative, Regenerative Medicine, Biotechnology, Stem Cell Therapy, Neuroprosthetics, Neurological Conditions
Received: January 1, 2025 **Accepted:** February 25, 2025 **Published:** February 28, 2025

ABSTRACT

Neurodegenerative diseases (NDDs) pose significant medical challenges, leading to progressive neuronal loss and functional decline. Current treatments primarily focus on symptom management rather than addressing the underlying pathology. Stem cell therapy and neuroprosthetics have emerged as two promising, yet distinct, approaches to mitigating the effects of NDDs. Stem cell therapy aims to regenerate or repair damaged neural tissue, while neuroprosthetics, including deep brain stimulation (DBS) and brain-computer interfaces (BCIs), modulate brain activity and restore lost functionality. This paper explores the potential synergy of combining these therapies to address both cellular regeneration and functional impairment. By integrating stem cell therapy's regenerative capabilities with neuroprosthetics' capacity to enhance neural communication, this approach could provide a more comprehensive strategy for treating NDDs. However, significant challenges remain, including ensuring stem cell survival and integration, optimizing neuroprosthetic interfaces, and addressing ethical considerations. While pre-clinical and early clinical studies have shown promising results, further research is necessary to establish the long-term efficacy and safety of this combined therapeutic model. Advancing this interdisciplinary approach credefine treatment paradigms for neurodegenerative conditions and improve patient outcomes.

1. INTRODUCTION

Neurodegenerative diseases (NDDs) impact millions of lives globally, becoming an ever-growing concern. Neurological conditions have undoubtedly become the leading cause of illness and disability worldwide, increasing by 18% since 1990 according to the World Health Organization in 2024 [1]. In my article, my objective is to present the potential of an integrative, multidisciplinary paradigm for the treatment of

neurodegenerative disorders, leveraging the synergistic application of neural stem cell transplantation in conjunction with the biotechnological innovation of neuroprosthetics. Combining cell-based therapies, biomaterials, gene therapies, and neurorehabilitation techniques offers a promising path forward. For example, stem cells can provide replacement neurons, while biomaterials offer scaffolds that support cell survival and tissue growth. Concurrently, gene therapies can enhance the regenerative potential of transplanted cells and host tissues by promoting axon growth and protecting neurons from degeneration. These approaches are not isolated but can complement one another. Together, these strategies have the potential to form a cohesive framework that targets multiple barriers to neural regeneration, accelerating progress in restoring function. The synergy between biological, technological, and rehabilitative solutions can offer hope for lasting recovery.

2. DEFINITION OF A NEURODEGENERATIVE DISEASE

Neurodegenerative diseases are a classification of disorders that are characterized by progressive neuronal degeneration, causing a gradual loss (and in certain levels of progression, cellular death) of neurons in the central nervous system (CNS). It is, in basic terms, defined as "a type of disease in which cells of the central nervous system stop working or die. Neurodegenerative disorders usually get worse over time and have no cure. They may be genetic or be caused by a tumor or stroke. Neurodegenerative disorders also occur in people who drink large amounts of alcohol or are exposed to certain viruses or toxins. Examples of neurodegenerative disorders include Alzheimer's disease and Parkinson's disease" [2]. This degree of progressive neuronal deterioration gives rise to permanent damage, considering that the regenerative capacity of the central nervous system is virtually nonexistent. NDDs manifest themselves in varying degrees of cognitive impairment, sensory and motor dysfunction, and in some instances, partial or complete paralysis. Therapeutic interventions remain limited, and no definitive cures for neuronal degeneration or cell death have been identified to date [3].

For example, Alzheimer's disease is commonly treated with cholinesterase inhibitors and NMDA receptor antagonists, which can provide temporary cognitive benefits, but they do not prevent neuronal loss [4]. Parkinson's disease is managed with dopamine replacement therapies, such as levodopa, which alleviate motor symptoms but become less effective over time and can lead to severe side effects like dyskinesia [5]. Across all NDDs, no current therapy can regenerate lost neurons or restore full function. This limitation underscores the extremely urgent need for innovative approaches like stem cell therapy and neuroprosthetics, which hold promise for cell regeneration, neural repair, and functional restoration beyond what traditional medications and therapies can achieve at this time.

NDDs arise from progressive dysfunction and loss of neurons, usually due to genetic, environmental, or age-related factors. The pathophysiology of NDDs is characterized by protein misfolding, mitochondrial dysfunction, oxidative stress, and neuroinflammation, all of which heavily contribute to neuronal death. In diseases like Alzheimer's or Parkinson', the accumulation of toxic protein aggregates and leads to synaptic dysfunction and widespread neurodegeneration throughout the entire central nervous system. Over time, these conditions advance from subtle cognitive/motor/sensory impairments to severe disability, because affected brain regions experience irreversible neuronal loss. As we will discuss later, neurons have a limited regenerative capacity, making this progressive deterioration cause functional decline in quality of life. Current treatments, such as physical therapy, medications, or psychiatry, primarily focus on symptom management as opposed to halting or reversing neuronal loss, and this highlights the urgent need for regenerative therapies. "Adult-onset neurodegenerative diseases (NDs) comprise a heterogeneous group of neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and many others. Despite their different etiology and symptomatic manifestations, all NDs feature a progressive loss of selected neuronal populations" [6]. All forms of neurodegenerative diseases above affect patients in a distinct and debilitating way. Neurodegenerative diseases encompass a range of disorders, each with its own pathophysiological distinctions. Despite these differences in pathology, these disorders share a common feature: the irreversible loss of neurons, which severely and

urgently impacts patient's independence and quality of life.

Challenges in Neural Regeneration

Neurodegenerative diseases involve damage to nervous tissue. Nervous tissue is one of the most highly specialized and vital tissues in the human body, serving as the foundation of the body's communication system. It is integral to the transmission and processing of information, the coordination of sensory input and output, and the initiation of responses (such as muscle contraction or hormone secretion) based on external stimuli. It sends as well as receives electrochemical signals that inform the body and the brain. This tissue is specifically found in the central nervous system and the peripheral nervous system (PNS). This is crucial because the capacity for growth and repair of this tissue differs between the different divisions of the nervous system. Within narrow parameters, regeneration is possible in the PNS. However, the CNS has a much more limited regenerative capacity—neurons in the CNS rarely regenerate due to the presence of inhibitory molecules and the formation of glial scars, which actively block axonal growth. "Axon regeneration in the mature mammalian central nervous system is extremely limited after injury" [7]. This renders nervous tissue particularly susceptible to damage or injury. This has substantial implications regarding neurodegenerative disorders. When neurons are damaged or cease to function completely, the consequences range from loss of sensory and motor function to complete cognitive impairment.

The nervous system relies solely on its plasticity, which is the ability of neurons to form new connections and adapt their functions to compensate for damage. Neurons are considered post-mitotic, meaning they do not divide once they are fully formed, and they do not regenerate. Because they are amitotic, they require glial cells to modulate neuronal activity, support neurons, and protect the brain from damage. Dysfunction of either of these types of cells found in nervous tissue can contribute to the cause of neurodegenerative diseases. Therefore, treatments for neurodegenerative diseases may involve restoring the function of both neurons and glial cells.

3. CELL-BASED THERAPIES

This is the purpose of stem cell therapy (also referred to as regenerative therapy), which possesses the capability to repair compromised or damaged nervous tissue, restore the functionality of neurons and glial cells and rehabilitate damaged neural circuits through the integration of differentiated cells, thereby promoting regeneration. Advancements in treatments like stem cell therapy and neuroprosthetics carry significant potential to enhance the central nervous system's regenerative capacity and thereby improve the prognosis of individuals diagnosed with NDDs.

"Over the past 20 years, regenerative cell therapy, also known as stem cell therapy, has provided an excellent opportunity to investigate potentially powerful innovative strategies for treating neurodegenerative diseases. This is due to stem cells' capability to repair injured neuronal tissue by replacing the damaged or lost cells with differentiated cells, providing a conducive environment that is in favor of regeneration, or protecting the existing healthy neurons and glial cells from further damage" [8]. Stem cell therapy can additionally serve to address the inflammatory environment that contributes to disease progression. "Stem cell therapy enables regeneration of neural tissue which ameliorates neurodegeneration occurring at different levels of the neuronal circuitry" [9].

3.1. Stem Cell Categories

Stem cells are entirely unique in their ability to proliferate, renew themselves, and differentiate into specialized cell types. There are several categories of stem cells, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem cells, which are multipotent (NSCs). These categories are all distinguished by their potential to generate different cell types, and the methods by which they are obtained. Harvesting ESCs, for example, raises severe ethical concerns. Grasping the distinct properties of each stem cell type is vital in assessing how regenerative therapies are

capable of influencing disease progression. The choice of stem cell is heavily dependent on the specific outcome we are aiming to achieve. Contextually, I am placing my focus primarily on neural stem cells, as they are the most relevant to treating NDDs.

3.2. Neural Stem Cells

"Neurodegenerative diseases are disabling and fatal neurological disorders that currently lack effective treatment. Neural stem cell (NSC) transplantation has been studied as a potential therapeutic approach and appears to exert a beneficial effect against neurodegeneration via different mechanisms, such as the production of neurotrophic factors, decreased neuroinflammation, enhanced neuronal plasticity and cell replacement. Thus, NSC transplantation may represent an effective therapeutic strategy" [10]. "Neural stem cells from specific brain areas or developed from progenitors of different sources are of therapeutic potential for neurodegenerative diseases" [11].

The first point we will discuss in relation to NSCs is that they are specialized and targeted for the brain and spinal cord, the primary regions affected by neurodegenerative diseases. The hallmark of NDDs is the gradual deterioration of neurons, which leads to a myriad of symptoms. Neural stem cells are targeted, and capable of differentiating into the various types of cells that comprise the nervous system. They can differentiate into neurons, which are the primary functional cells of the brain and spinal cord which transmit electrical impulses. Astrocytes, which are cells that support and nourish neurons, maintain the blood-brain barrier, and repair tissue damage. Finally, they can also become oligodendrocytes, which are responsible for the formation of myelin (which functions to insulate neurons and expedites signal transmission). These are all key cell types in CNS function.

NSCs exhibit a natural propensity to populate the nervous system and regenerate the exact cell types required in areas of injury or damage. While other stem cell variants, like MSCs or iPSCs, possess the ability to differentiate into neurons, NSCs are inherently specialized to function within the CNS, making them optimal candidates for the application of stem cell therapy.

The second point is neuronal regeneration. One of the core challenges in treating NDDs is that neurons, once damaged, are not made for self renewal. This has been a primary focus of this article, so you are already familiar with this concept. This is because, unlike many other tissues, neurons are post-mitotic (they do not divide and replicate). NSCs, however, possess the ability to regenerate neurons. They differentiate into new, healthy neurons, replacing those lost to disease. This regeneration process is crucial in situations like Parkinson's Disease (PD), where dopamine-producing neurons are lost, or Alzheimer's, where neurons involved in memory and cognitive function degenerate. By introducing NSCs into the affected regions of the CNS, there is a chance to restore lost neuronal populations, or at least foster neurogenesis (the formation of altogether new neurons), which is rare in adult human brains. "The mammalian brain has the capacity to repair itself through neurogenesis and gliogenesis to a limited degree; however, endogenous neurogenesis and gliogenesis decrease significantly with age and are unable to regenerate enough brain cells alone" [12]. An additional point is that NSCs can assist in mitigating the effects of neurodegeneration by providing a source of new neurons that may help compensate for the loss of function caused by the disease [13].

Thirdly, one of the biggest obstacles in treating NDDs is ensuring that the transplanted stem cells integrate properly into existing neural networks. NSCs are particularly advantageous in this regard due to their ability to adapt to and integrate with the existing neural tissue.

After transplantation, NSCs can form connections with surrounding neurons, restoring neural circuits that may have been disrupted by disease. This adaptability is crucial. NSCs can integrate into the existing motor control pathways, potentially restoring some degree of movement function. NSCs have a degree of plasticity, which you recall I mentioned the nervous system relies on, which allows them to form functional connections with existing neurons. "A large number of newborn neurons can be generated from adult NSCs, and integrate into pre-existing neural circuits. Adult neurogenesis in either the SVZ [subventricular zone] or the SGZ [subgranular zone] is also highly sensitive to environmental cues, physiological stimuli and neuronal activity, suggesting that the tailored addition of new neurons might serve specific neuronal functions"

[14]. For example, if transplanted into the hippocampus, the logical conclusion is that NSCs would differentiate into neurons that support cognitive functions, therefore mitigating the symptoms of memory loss.

The brain has a limited natural ability to repair itself, but NSCs can enhance this process by replenishing the damaged cell types (neurons, glial cells) and improving the overall healing environment. Their ability to integrate into the brain's existing architecture helps to restore function rather than just providing isolated new cells.

To summarize, neural stem cells are the most appropriate stem cell for treating neurodegenerative diseases because they are naturally equipped to regenerate the specific types of cells needed in the central nervous system. They not only possess the ability to repair damage and reconstruct neurons, but additionally, integrate with previously existing neural circuits which offer the possibility to restore lost functions (*i.e.*, motor function, sensory function, etc).

3.3. Concerns with Cell-Based Therapy

Stem cell therapy, in particular neural stem cells, holds great promise for treating neurodegenerative disorders, but it also raises several ethical concerns. These concerns are largely related to the sourcing, use, and potential consequences of stem cell treatments.

The source from which NSCs are derived can raise ethical concerns, specifically when embryonic stem cells are used, as this involves the destruction of embryos. Although NSCs can be obtained from various sources, such as adult tissues or iPSCs, ESCs remain a common focus of debate due to their ability to differentiate into any cell type. The most reasonable option is to procure NSCs from adult tissues. Using adult-sourced stem cells negates many of the ethical concerns associated with embryonic sources. However, NSCs still raise questions about the ethical sourcing of brain tissue.

Another primary concern is regulation and safety, taking into consideration that the usage of NSCs for regenerative medicine is still an emerging field. The lack of sufficient research can lead to unsafe or unethical practices. There are clinics that offer stem cell treatments that have not been approved by regulatory bodies, like the U.S. Food and Drug Administration (FDA). These unregulated treatments can subject patients to extreme risk including infections, rejection, and tumor formation due to transplanted cells becoming cancerous. NSCs have the potential to, in rare situations, form teratomas if they divide uncontrollably. These risks must be carefully weighed against the potential benefits of regeneration.

Long term efficacy is still in question. In light of the fact that NSC therapy is relatively new, there is a great deal of uncertainty surrounding the long term effects of this treatment.

Furthermore, there are logistical challenges involving optimizing delivery methods and ensuring cell survival. Many of these challenges are largely due to the blood-brain barrier (BBB), which is a highly selective permeability barrier that protects the brain from harmful substances in the bloodstream. It serves to create what is basically a separate immune system for the brain. This barrier restricts the passage of many therapeutics, including stem cells, which makes it difficult for them to reach the targeted brain areas. Overcoming the BBB is complicated, as any attempt to bypass or disrupt it must be done cautiously to avoid damaging this protective layer, which could lead to inflammation, infections, or other neurological issues. Even if stem cells manage to successfully reach the brain, ensuring their survival and integration into brain tissue presents another significant hurdle. The brain's microenvironment, which includes immune response, tissue-specific factors, and the complex network of neurons, can hinder the cells from thriving and differentiating as intended. "The efficacy of cell therapy, which involves stem cell transplantation into the CNS to replace damaged tissue, has been limited due to low cell survival and integration upon transplantation, while delivery of therapeutic molecules to the CNS using conventional methods, such as oral and intravenous administration, have been limited by diffusion across the blood-brain/spinal-cord barrier" [15].

Delivering stem cells to the correct location in the body, particularly to the brain or central nervous system—especially in the context of neurodegenerative diseases—is one of the most significant logistical hurdles in stem cell therapy and research. Stem cells absolutely *must* be delivered *directly* to the affected area to maximize their regenerative effect. In the case of NDDs, this means targeting specific regions of the

brain that are degenerating. Direct delivery methods, such as injections into the cerebrospinal fluid or intracranial injections, can be invasive, dangerous, and do not guarantee that the stem cells will successfully reach the desired target. Scientists are still researching how to optimize precise methods of delivery, such as utilizing nanotechnology, micro-catheters, or even biomaterials that can specifically guide stem cells directly to the affected areas [16]. In disorders such as AD, PD, and HD, the progression and localization of neuronal degeneration vary widely, complicating the task of identifying the optimal sites for stem cell administration. The heterogenous nature of these diseases means that a one-size-fits-all approach to targeting is inadequate, as markedly distinct brain regions may be involved in each case. Moreover, the anatomical complexity of the brain, including the presence of deep-seated structures and the protective blood-brain barrier, further limits the precision with which stem cells can be delivered to the intended regions. Current methods, such as intracerebral injections or catheter-based delivery have been employed, but they often lack the accuracy required to target small or deep areas of the brain effectively.

Once stem cells are successfully delivered to the target area, ensuring their survival, proper integration, and effective differentiation is another challenge. Stem cells are highly sensitive to their environment. The conditions within the host tissue can impact their survival quite significantly. In regard to NDDs, it isn't necessarily an ideal treatment option because the brain's environment is usually extremely hostile, with factors such as oxidative stress, inflammation, and a lack of necessary growth factors impeding cellular proliferation, differentiation, and survival. "The 'niche' is defined as the microenvironment that intimately supports and tightly regulates stem cell behaviors, including their maintenance, self-renewal, fate specification and development" [17]. Scientists are researching the creation of a more favorable microenvironment to support survival, such as incorporating neurotrophic factors or using scaffolds to protect the cells from hostile conditions.

Cell viability post transplantation is critical to regeneration. After transplantation, the cells are facing harsh biological conditions that include immune response, malnutrition, and physically damaged tissue. To address this, researchers are exploring strategies to precondition cells to enhance resiliency and adaptability before transplantation.

In order for stem cells to provide the therapeutic benefits we want to achieve, they must not only survive, but proliferate and differentiate into the correct cell types. To treat a neurodegenerative disorder, the goal is for them to differentiate into neurons or glial cells in the brain. Controlling the proliferation is essential in avoiding the formation of teratomas, which is a risk if cells begin uncontrollably dividing. This requires tightly regulating the cellular environment, ensuring that stem cells only proliferate and differentiate as needed. "Since stem cells can respond to its microenvironment to undergo differentiation, this could be another challenge to ensure that after drug delivery the stem cells do not form a specialized cell within the brain" [18].

Conveniently, stem cells have natural mechanisms that enable them to migrate to areas of tissue damage, a process defined as "homing." The process is not always efficient, especially when dealing with NDDs that cause widespread neuronal degeneration. Researchers are working on understanding how to enhance the homing of stem cells to the damaged regions of the CNS. Stem cells can, as an example, be engineered to express certain proteins that make them more likely to be attracted to areas of inflammation or neurodegeneration. Additionally, the complexity of brain regions involved in neurodegenerative diseases further complicates stem cell targeting. Unlike more straightforward damage where the site of injury is well defined, brain regions affected by neurodegeneration can vary between patients, and the specific cells that need to be replaced may vary. Targeting specific brain structures, such as the hippocampus, requires precision. It is important that stem cells populate the intended area and it is not easy to track transplanted cells. Researchers are still exploring how to use non-invasive techniques to monitor [19]. Even when stem cells reach the intended area, factors such as neuronal loss, the presence of glial cells, and inflammatory processes all affect how well the stem cells can integrate into existing tissue.

Direct delivery methods, while necessary, come with risks such as infection, inflammation, and injury to surrounding tissues, all of which can impact the overall success of the procedure. Achieving targeted

delivery within the brain also requires advanced technologies to guide the cells accurately, which remains a significant obstacle. Even when stem cells reach the intended regions, they must survive and integrate into the existing neural circuits. Given the brain's complexity, and the challenges associated with repairing damaged neural tissue, the process of stem cell differentiation into functional neurons or glial cells becomes a delicate balance that must be maintained.

These logistical challenges are multifaceted and require coordinated efforts across multiple fields of research. Optimizing delivery methods, ensuring stem cell survival and proliferation, effectively targeting damaged tissue, and monitoring success are all critical aspects that must be addressed.

4. BIOTECHNOLOGY AND NEUROPROSTHETICS

Biotechnology is a rapidly evolving field that harnesses biological systems to develop innovative products and technologies that address challenges across various sectors, the relevant one being medicine. This interdisciplinary field combines principles from biology, chemistry, engineering, and computer science to manipulate living organisms at the molecular or cellular level.

Stem cell therapy is promising for repairing neural damage and restoring function in NDDs. However, while stem cells can regenerate tissue, the functional restoration of neural circuits can be more challenging. This is where neuroprosthetics, such as deep brain stimulators and brain-computer interfaces, come into play. These devices work by stimulating neural circuits and facilitating communication between brain regions, addressing functional impairments. When combined, stem cell therapy and neuroprosthetics have the potential to offer a dual solution: stem cells regenerate damaged tissue, while neuroprosthetics help restore communication and optimize brain activity in these newly repaired regions. Together, these therapies could address both the biological damage and the functional deficits caused by NDDs, leading to improved patient outcomes.

Neuroprosthetics present a promising frontier in the treatment of NDDs, providing hope for patients with conditions such as Parkinson's disease (PD), Alzheimer's disease (AD), and spinal cord injuries. These devices, namely deep brain stimulators (DBS), have been shown to be effective in alleviating certain symptoms of PD, such as tremors, rigidity, and motor dysfunction. DBS involves implanting electrodes in specific regions of the brain that are responsible for controlling movement. These electrodes send electrical impulses to modulate abnormal brain activity.

Emerging neuroprosthetic techniques are also focusing on bridging damaged neural circuits, which can help restore both lost mobility, as well as cognitive function, which has numerous implications for researching NDD treatment. Advances in brain-computer interfaces (BCIs) are showing potential in allowing patients to control external devices or even interact with their own bodies by bypassing neural pathways that have been damaged. For example, individuals with spinal cord injuries are now able to use advanced BCIs to regain some degree of control over their limbs and other bodily functions. Similarly, and more importantly, cognitive neuroprosthetics aim to enhance or restore cognitive abilities by stimulating neural networks that have been compromised by NDDs. These systems act as a bridge, enabling communication between the affected brain regions and other parts of the body. In this vein, neuroprosthetics have the potential to partially restore functionality in areas of the brain that would otherwise be impaired by disease or injury, by bypassing damaged neural pathways; acting as a bridge to help the brain communicate with the body.

Concerns with Neuroprosthetics

While these types of biotechnology show a certain degree of promise to the medical field and advancing research in NDD treatments, they also raise significant ethical concerns. One of the primary issues revolves around patient autonomy and identity. The implantation and usage of neuroprosthetics may involve altering the individual's cognitive and emotional state, which can lead to unintended changes in personality and behavior, which is a risk many patients would not be willing to take. These accidental alterations would raise questions about the extent to which the individual still retains control over their identity. There is potential for neuroprosthetics to unintentionally modify an individual's mental state in ways that were not foreseen

or planned, therefore leading to ethical dilemmas regarding the preservation of personal identity. Neuroprosthetics face the additional hurdle of integration with the brain's neural circuits. The challenge of bridging the gap between synthetic devices and biological tissue remains one of the most significant barriers to achieving full functional restoration. These scientific challenges are compounded by the ethical concerns associated with stem cell sourcing, regulation, and the long-term effects of therapy, all of which must be considered in the development of safe and effective treatments, especially when discussing the combination.

Despite these challenges, neuroprosthetics remain a rapidly evolving and interesting field.

5. INTEGRATING A MULTIDISCIPLINARY APPROACH TO CELL-BASED THERAPY AND NEUROPROSTHETICS

Combining the usage of biotechnological neuroprosthetics and the regenerative capabilities of stem cell therapy represents a powerful, multifaceted approach to treating neurodegenerative diseases, potentially offering a synergistic effect that addresses both the underlying root causes and the symptoms of these conditions.

Stem cell therapy could be used to repair damaged neurons in areas of the CNS affected by NDDs. Neural stem cells, which can differentiate into various types of neurons and glial cells, may be introduced to regenerate the lost or damaged neural tissue. These stem cells could integrate into the existing neural circuits, replacing lost cells and potentially restoring some level of functionality to the affected brain regions.

An example of this would be in PD, where dopaminergic neurons are lost in the brain, stem cells could be used to regenerate dopamine-producing neurons, thereby addressing the root cause of motor symptoms. This regeneration would not fully cure the disease but it could assist in slowing the progression, and possibly mitigate some of its effects.

Neuroprosthetics, such as DBS or BCIs, could be used to manage the symptoms of NDDs by stimulating and modulating brain activity. These devices are typically used to bypass damaged neural pathways or stimulate neural circuits to restore or enhance functionality. In individuals with NDDs, where certain neural pathways are either damaged or have lost complete function, neuroprosthetics can act as a bridge, helping the brain to communicate more effectively with the body.

When we introduce a combination of these two treatments and hypothesize using them together, stem cell therapy and neuroprosthetic could complement each other to address both the biological damage and the functional impairments that result from this damage. Stem cells could regenerate or repair damaged cells and tissues, while neuroprosthetics could help modulate brain activity to optimize neural function and improve communication between brain regions.

By addressing the cellular and functional aspects of neurodegeneration, this combined approach has the potential to significantly enhance the patient's quality of life. This combination therapy might allow people with NDDs to regain greater autonomy, reducing their dependence on caregivers and improving their ability to perform daily tasks. While stem cell therapy focuses on regenerating and repairing the neural tissue, neuroprosthetics could help modulate brain activity to restore function partially or completely.

While using neuroprosthetics and stem cell therapy in conjunction with one another holds great promise, there are significant challenges to consider. These include ensuring the survival and integration of stem cells into existing neural circuits, developing precise and non-invasive methods for delivering stem cells to specific areas of the brain, and addressing the side effects or complications that could arise from long-term use of neuroprosthetics. Ethical concerns regarding unintentional cognitive, emotional, or behavioral alterations must be carefully considered.

Multiple studies have been conducted on using these two therapies in conjunction with each other and we have seen relative success in preclinical and early clinical studies, but it is still in the experimental phases, and its success on humans is uncertain [20-22]. For example, a phase 1 clinical trial evaluated the safety of human fetal neuron progenitor cell transplantation in patients with progressive multiple sclerosis (MS), indicating potential for neural repair [19]. It is a developing area of research. Integrating both approaches could significantly enhance the patient's prognosis—combining stem cell therapy's regenerative potential

with neuroprosthetics' functional support—there is a possibility of slowing disease progression. As research advances, a multidisciplinary approach utilizing both regenerative medicine and neurotechnology could offer the best option for CNS repair.

The transition of using stem cell therapy and neuroprosthetics in conjunction with each other going from experimental stages to routine clinical practice for the treatment of NDDs is hindered by several substantial barriers, encompassing scientific, technical, regulatory, and ethical issues. One of the foremost obstacles is the lack of a comprehensive understanding of the long-term behavior and effects of stem cells once they are implanted and integrated into brain tissue. While stem cells do show potential for replacing damaged neurons, there is insufficient evidence on their survival, integration, and differentiation into functional neural tissue over extended periods. Furthermore, ensuring the safety of these therapies is critical, as there is a risk of tumorigenesis or unwanted cellular differentiation, which could exacerbate the condition or lead to new complications. In addition to this point, while neuroprosthetics have shown promise in their field, developing devices that can seamlessly interface with the brain's complex neural networks remains a challenge. Achieving reliable, bidirectional communication between the brain and external prosthetic devices without causing adverse reactions, such as inflammation or immune rejection, remains an unresolved hurdle.

From a technical standpoint, the ability to accurately target and deliver stem cells or implant neuroprosthetics into specific brain regions is constrained by current limitations in imaging, precision delivery, and device miniaturization. The need for real-time, precise monitoring of cell behavior and prosthetic function further complicates this effort. Regulatory hurdles also play a significant role, as both stem cell-based therapies and neuroprosthetics must undergo extensive clinical trials to demonstrate their safety, efficacy, and long-term benefits. The lack of standardized protocols for these treatments means that clinical trials must be designed with caution, resulting in slow progress. Collectively, all of these challenges present barriers to advancing stem cell therapy and neuroprosthetics into mainstream clinical practice for neurodegenerative diseases.

6. CONCLUSION

The integration of stem cell therapy and neuroprosthetics represents an intriguing multidisciplinary approach to treating neurodegenerative diseases. While stem cells offer regenerative potential by repairing damaged neural tissue, neuroprosthetics provide functional modulation, bridging gaps in neural communication. Together, these therapies could mitigate disease progression, enhance neurological function, and improve patient autonomy. However, significant challenges remain, including optimizing stem cell integration, refining neuroprosthetic interfaces, and addressing long-term efficacy and ethical considerations. While preclinical and early clinical studies have demonstrated potential, further research is essential to validate the safety and effectiveness of this combined approach. As the field advances, leveraging both regenerative medicine and neurotechnology may offer the most comprehensive strategy for central nervous system repair and restoration.

REFERENCES

1. World Health Organization (2024, March 14) Over 1 in 3 People Affected by Neurological Conditions—The Leading Cause of Illness and Disability Worldwide. World Health Organization. https://www.who.int/news/item/14-03-2024-over-1-in-3-people-affected-by-neurological-conditions-the-leading-cause-of-illness-and-disability-worldwide
2. National Cancer Institute (n.d.) Neurodegenerative Disorder. U.S. National Institutes of Health. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/neurodegenerative-disorder
3. Shusharina, N., Yukhnenko, D., Botman, S., Sapunov, V., Savinov, V., Kamyshov, G., *et al.* (2023) Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression. *Diagnostics*, **13**, Article No. 573. https://doi.org/10.3390/diagnostics13030573

4. Ferrazzoli, D., Carter, A., Ustun, F.S., Palamara, G., Ortelli, P., Maestri, R., *et al.* (2016) Dopamine Replacement Therapy, Learning and Reward Prediction in Parkinson's Disease: Implications for Rehabilitation. *Frontiers in Behavioral Neuroscience*, **10**, Article No. 121. https://doi.org/10.3389/fnbeh.2016.00121
5. Danysz, W. and Parsons, C.G. (2003) The NMDA Receptor Antagonist Memantine as a Symptomatological and Neuroprotective Treatment for Alzheimer's Disease: Preclinical Evidence. *International Journal of Geriatric Psychiatry*, **18**, S23-S32. https://doi.org/10.1002/gps.938
6. Tesco, G. and Lomoio, S. (2022) Pathophysiology of Neurodegenerative Diseases: An Interplay among Axonal Transport Failure, Oxidative Stress, and Inflammation? *Seminars in Immunology*, **59**, Article ID: 101628. https://doi.org/10.1016/j.smim.2022.101628
7. Huebner, E.A. and Strittmatter, S.M. (2009) Axon Regeneration in the Peripheral and Central Nervous Systems. In: *Results and Problems in Cell Differentiation*, Springer, 305-360. https://doi.org/10.1007/400_2009_19
8. Sivandzade, F. and Cucullo, L. (2021) Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. *International Journal of Molecular Sciences*, **22**, Article No. 2153. https://doi.org/10.3390/ijms22042153
9. Sakthiswary, R. and Raymond, A.A. (2012) Stem Cell Therapy in Neurodegenerative Diseases: From Principles to Practice. *Neural Regeneration Research*, **7**, 1822-1831. https://doi.org/10.3969/j.issn.1673-5374.2012.23.009
10. De Gioia, R., Biella, F., Citterio, G., Rizzo, F., Abati, E., Nizzardo, M., *et al.* (2020) Neural Stem Cell Transplantation for Neurodegenerative Diseases. *International Journal of Molecular Sciences*, **21**, Article No. 3103. https://doi.org/10.3390/ijms21093103
11. Gincberg, G., Arien-Zakay, H., Lazarovici, P. and Lelkes, P.I. (2012) Neural Stem Cells: Therapeutic Potential for Neurodegenerative Diseases. *British Medical Bulletin*, **104**, 7-19. https://doi.org/10.1093/bmb/lds024
12. Kim, I., Park, J., Kim, B., Hwang, K. and Song, B. (2021) Recent Advances in Stem Cell Therapy for Neurodegenerative Disease: Three Dimensional Tracing and Its Emerging Use. *World Journal of Stem Cells*, **13**, 1215-1230. https://doi.org/10.4252/wjsc.v13.i9.1215
13. Ma, D.K., Bonaguidi, M.A., Ming, G. and Song, H. (2009) Adult Neural Stem Cells in the Mammalian Central Nervous System. *Cell Research*, **19**, 672-682. https://doi.org/10.1038/cr.2009.56
14. Morgado, A.L. and Gaspar, P. (2013) Stem Cell-Based Therapies for Neurodegenerative Diseases: Current Status and Future Prospects. *Stem Cell Research & Therapy*, **3**, 24.
15. Tam, R.Y., Fuehrmann, T., Mitrousis, N. and Shoichet, M.S. (2013) Regenerative Therapies for Central Nervous System Diseases: A Biomaterials Approach. *Neuropsychopharmacology*, **39**, 169-188. https://doi.org/10.1038/npp.2013.237
16. Bible, E., Dell'Acqua, F., Solanky, B., Balducci, A., Crapo, P.M., Badylak, S.F., *et al.* (2012) Non-Invasive Imaging of Transplanted Human Neural Stem Cells and ECM Scaffold Remodeling in the Stroke-Damaged Rat Brain by 19F- and Diffusion-MRI. *Biomaterials*, **33**, 2858-2871. https://doi.org/10.1016/j.biomaterials.2011.12.033
17. Rowland, N.C., Kalia, S.K., Kalia, L.V., Larson, P.S., Lim, D.A. and Bankiewicz, K.S. (2016) Merging DBS with Viral Vector or Stem Cell Implantation: "Hybrid" Stereotactic Surgery as an Evolution in the Surgical Treatment of Parkinson's Disease. *Molecular Therapy—Methods & Clinical Development*, **3**, Article No. 15051. https://doi.org/10.1038/mtm.2015.51
18. Gupta, A., Vardalakis, N. and Wagner, F.B. (2023) Neuroprosthetics: From Sensorimotor to Cognitive Disorders. *Communications Biology*, **6**, Article No. 14. https://doi.org/10.1038/s42003-022-04390-w
19. Genchi, A., Brambilla, E., Sangalli, F., Radaelli, M., Bacigaluppi, M., Furlan, R., *et al.* (2023) Neural Stem Cell Transplantation in Patients with Progressive Multiple Sclerosis: An Open-Label, Phase 1 Study. *Nature Medicine*, **29**, 75-85. https://doi.org/10.1038/s41591-022-02097-3
20. Barker, R.A., Björklund, A., Frucht, S.J. and Svendsen, C.N. (2021) Stem Cell-Derived Dopamine Neurons: Will

They Replace DBS as the Leading Neurosurgical Treatment for Parkinson's Disease? *Journal of Parkinson's Disease*, **11**, 909-917. https://doi.org/10.3233/jpd-219008

21. Namiot, E.D., Niemi, J.V.L., Chubarev, V.N., Tarasov, V.V. and Schiöth, H.B. (2022) Stem Cells in Clinical Trials on Neurological Disorders: Trends in Stem Cells Origins, Indications, and Status of the Clinical Trials. *International Journal of Molecular Sciences*, **23**, Article No. 11453. https://doi.org/10.3390/ijms231911453
22. Iwasa, S.N., Liu, X., Naguib, H.E., Kalia, S.K., Popovic, M.R. and Morshead, C.M. (2024) Electrical Stimulation for Stem Cell-Based Neural Repair: Zapping the Field to Action. *Eneuro*, **11**, ENEURO.0183-24.2024. https://doi.org/10.1523/eneuro.0183-24.2024